b-catenin accumulation is often found in lung tumors, but only a few patients have mutations in b-catenin gene. In addition, activated p53 downregulates b-catenin. Therefore, we postulated that alteration of the degradation complex AXIN2 (axis inhibition protein 2) and betaTrCP (b-transducin repeat-containing protein) and p53 regulation could result in b-catenin protein accumulation in lung cancer. Using the immunohistochemical and sequencing analyses, we found that patients with b-catenin accumulation without mutation were associated with patients with p53 overexpression and low AXIN2 expression (P ¼ 0.023B0.041). Alteration of AXIN2 was associated with poor survival in early stage patients (P ¼ 0.016). Low expression of AXIN2 and betaTrCP was significantly associated with promoter hypermethylation and histone deacetylation. Ectopic expression and knockdown of p53, AXIN2 and betaTrCP genes in A549 (p53 wild-type) and H1299 (p53 null) lung cancer cell lines showed cooperation between p53 and AXIN2/betaTrCP in the reduction of b-catenin expression. Our clinical and cell model findings provide new evidence that epigenetic silencing of AXIN2/betaTrCP in the degradation complex and deregulation of p53-mediated control lead to wild-type b-catenin nuclear accumulation in non-small cell lung cancer tumorigenesis. In addition, a high level of p53 downregulates the b-catenin expression, but this effect is attenuated by non-functional AXIN2 or betaTrCP in lung cancer.
Introduction
Lung cancer is one of the most common malignancies and is the leading cause of cancer death in industrialized countries (Minna et al., 2002) . Therefore, an understanding of the multiple genetic and epigenetic alterations in lung tumorigenesis is important to develop early diagnostic and preventive biomarkers and new therapeutic targets for this disease. Recently, our genomewide loss of heterozygosity (LOH) study showed that a moderate to high frequency of LOH at the chromosomal regions 5q22.2, 10q24.31 and 17q24.2 are found in non-small cell lung cancer (NSCLC) patients (Tseng et al., 2005) . Interestingly, these deleted regions are close to gene loci encoding the APC (adenomatosis polyposis coli), betaTrCP (b-transducin repeat-containing protein) and AXIN2 (axis inhibition protein 2) proteins, which are tumor suppressor-like proteins involved in regulating b-catenin degradation. Importantly, b-catenin deregulation leads to malignant transformation such as lung cancer (Kase et al., 2000) . We thus postulated that deregulated b-catenin might result from the alterations of these genes encoding the b-catenin destruction complex and could be involved in NSCLC tumorigenesis.
b-catenin is a major component of the Wnt signaling pathway involved in vertebrate development, morphogenesis, cellular proliferation, differentiation, motility and tumorigenesis (Wodarz and Nusse, 1998; Polakis, 2000) . In normal and non-stimulated cells, the majority of b-catenin proteins is present in adherens junctions with very little in cytoplasmic or nuclear fractions, as it undergoes rapid turnover by a multiprotein destruction complex containing AXIN1, AXIN2, APC and glycogen synthase kinase 3b (GSK3b) (Chen et al., 2000) . AXIN1 and AXIN2 serve as scaffold proteins maintaining the configuration of this complex and facilitating GSK3b to phosphorylate b-catenin to create a recognition motif for betaTrCP, a ubiquitin ligase, thus providing for degradation through the ubiquitin-proteasome pathway (Taketo, 2004) . Therefore, loss of function in Axin complex and betaTrCP protein would be predicted to cause effectively increased Wnt/b-catenin signaling. Activated Wnt signaling inhibits the phosphorylation of b-catenin, thereby causing b-catenin to dissociate from the Axin complex and preventing its degradation. This results in b-catenin accumulation in the cytoplasm and translocation to the nucleus, where it binds to the T-cell specific factor/ lymphoid enhancer binding factor 1 and activates the expression of target genes such as AXIN2, betaTrCP, cjun, c-myc and cyclin D1 (Spiegelman et al., 2000; Lustig et al., 2002) .
Recently, a cross talk between p53 and b-catenin is suggested by clinical and cell model studies. For example, cases of colon cancer that showed b-catenin accumulation also showed a high frequency of p53 overexpression (Kinzler and Vogelstein, 1996) . It has been reported that b-catenin accumulation can promote the increase of wild-type p53 (Damalas et al., 1999) and that activated p53 or overexpression of p53 downregulates b-catenin in human cancer cell lines (Damalas et al., 1999; Sadot et al., 2001; Chung et al., 2004) . The feedback loop proposed was that p53-mediated reduction in b-catenin probably exerted its effect by accelerating the degradation of b-catenin (Sadot et al., 2001) . It is thus tempting to speculate that the alteration of the degradation system (APC, GSK3b, AXIN1, AXIN2 and betaTrCP) blocks the downregulation of b-catenin by p53.
Aberrant Wnt/b-catenin signaling is commonly observed in certain human cancers and several studies suggest that mutations of b-catenin result in tumorigenesis (Moon et al., 2004; Gregorieff and Clevers, 2005; Mazieres et al., 2005) . The mutations of APC and AXIN2 are also a common occurrence in colorectal carcinomas (Morin et al., 1997; Liu et al., 2000) . However, in lung cancer, mutation of APC, AXIN2 or b-catenin are rarely seen (Mazieres et al., 2005; Hughes and Brady, 2006) , and therefore nuclear b-catenin accumulation may be a result of mechanisms other than mutation of these genes. In addition, the relationship between destruction complex in b-catenin and p53 expression in lung cancer has not been documented in detail. In this study, we first confirmed that b-catenin indeed accumulated in the absence of b-catenin gene mutation in most NSCLC specimens. Therefore, we focused on the genetic and epigenetic alterations of upstream effectors of b-catenin degradation components (such as AXIN2 and betaTrCP) to determine whether alterations were associated with the clinical and biological behavior of tumors in NSCLC patients. In addition, experiments on NSCLC cell lines after treatment with demethylation reagent and histone deacetylase inhibitor prove that epigenetic silencing is the predominant mechanism of AXIN2 and betaTrCP inactivation. Furthermore, we validated that destruction complex augments the reciprocal relationship of p53 and b-catenin expression by knockdown or ectopic expression of AXIN2, betaTrCP and p53 gene in lung cancer cells. Our data indicated the cooperation between p53 and AXIN2/betaTrCP in the reduction of b-catenin expression.
Results
Nuclear b-catenin accumulation without gene mutation in NSCLC patients Immunohistochemical staining was performed on 110 tumor samples. Forty-five lung cancers (41%) showed b-catenin protein accumulation (Figures 1a and b) . To examine the possibility that the nuclear b-catenin accumulation resulted from DNA mutation, exon 3 of b-catenin, the mutational hotspot region containing the GSK3b phosphorylation sites, was screened for activating mutations by direct sequencing of 45 NSCLC samples with b-catenin accumulation. Our results showed that no b-catenin mutation was identified (Supplementary Figure 1) .
Correlation of b-catenin accumulation and the expressions of AXIN2, betaTrCP, APC and p53 proteins in NSCLC patients We therefore attempted to verify the hypothesis that b-catenin accumulation in NSCLC may be through p53 overexpression and deregulation of the component of the b-catenin degradation machinery, that is, AXIN2, betaTrCP and APC. The immunohistochemical data indicated that 35%, 18% and 10% of tumors showed an absence or low expression of AXIN2, betaTrCP and APC proteins, respectively. Interestingly, we found p53 overexpression in 62% of the tumors examined ( Figures  1a and b) . Notably, in patients with low expression of AXIN2, b-catenin frequently accumulation associated with p53 overexpression (P ¼ 0.041; Figure 1c ). In addition, of 45 tumors with b-catenin accumulation, low expression of AXIN2 was associated with p53 overexpression (P ¼ 0.023; Figure 1d ).
Genetic and epigenetic alteration analyses of APC, AXIN2 and betaTrCP genes in NSCLC patents To investigate whether genetic alterations are involved in changes in gene expression, we studied allelic loss of the APC, AXIN2 and betaTrCP genes using LOH assay in this cohort of NSCLC patients (Figure 2a ). Allelic typing found that LOH in the AXIN2, betaTrCP and APC loci were 43%, 30% and 12%, respectively, of informative cases.
Semi-quantification reverse transcriptase (RT)-PCR analysis was then conducted to validate the mRNA expression of AXIN2 and betaTrCP genes (upper panel of Figure 2b ). Analysis was not performed for APC because of its low alteration frequency in protein and LOH assays. Decreased or absent AXIN2 and betaTrCP transcripts were found in 37% and 19% of NSCLC, respectively (Figure 2c ).
To determine whether epigenetic change altered gene expression, we studied promoter hypermethylation of the AXIN2 and betaTrCP genes using methylationspecific PCR (MSP) analysis in this cohort of NSCLC patients (lower panel of Figure 2b ). As shown in Figure 2c , promoter hypermethylation of the AXIN2 and betaTrCP genes occurred in 52% and 53% of the Correlations between protein expression pattern mRNA expression pattern, and DNA alteration status were subsequently investigated ( Figure 2d ). Aberrant protein expression was significantly associated with low mRNA expression (AXIN2, Po0.001; betaTrCP, Po0.001) and with promoter hypermethylation (AXIN2, P ¼ 0.039) but not with LOH of both genes.
Reactivation of AXIN2 and betaTrCP by 5-aza-2 0 -deoxycytidine and suberoylanilide hydroxamic acid treatments in lung cancer cell lines To confirm whether promoter hypermethylation of AXIN2 and betaTrCP caused loss of their gene expression, two NSCLC cell lines, CL1-5-F4 cell showing low expression of both AXIN2 and betaTrCP and A549 cell showing low expression of AXIN2 were treated with the demethylating agent 5-aza-2 0 -deoxycytidine (5-aza-dC). As shown in Figures 3a-c, treatment with 5-aza-dC successfully restored mRNA and protein expressions and demethylated the promoter region of genes, which were originally methylated in these cells. In addition, mRNA expression levels of c-myc and cyclin D1, which are targets for b-catenin transactivation, apparently decreased after restoration of AXIN2 and betaTrCP expressions (Figure 3d ).
Histone deacetylation of the promoter is another well documented epigenetic alteration (Jones and Baylin, 2007) . We therefore treated CL1-5-F4 and A549 cells with histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). As shown in Figure 3 , treatment with SAHA also restored mRNA/protein expression of AXIN2 and betaTrCP genes along with reactivation of b-catenin transactivation.
Knockdown or ectopically expressed AXIN2, betaTrCP and p53 controlled b-catenin expression level in lung cancer cell lines To examine the reciprocal relationship between b-catenin and p53 expression as well as the effect of AXIN2 and betaTrCP, we used shRNA technology to knock down the p53 gene and ectopically introduced AXIN2 in A549 cell (with wild-type p53 and low level of AXIN2 (epigenetically silenced)). Western blot analysis indicated that p53 knockdown induced a high level of b-catenin in A549 cells (lane 2 of Figure 4a ). Ectopically expressed AXIN2 in p53 knockdown A549 cells resulted in a substantial decrease in b-catenin protein expression (lane 3 of Figure 4a ). In addition, ectopically expressed To validate the effect of AXIN2 and betaTrCP on the reciprocal relationship between b-catenin and p53 expression, the ability of excess AXIN2, betaTrCP and p53 to regulate b-catenin protein expression was also examined in H1299 cells (with p53 null background). In H1299 cells harboring ectopically expressed p53 gene, a lower level of b-catenin protein compared to the original H1299 cells was observed (lanes 2 and 6 of Figure 4b ). The level of b-catenin protein was even lower in H1299 cells, which ectopically expressed both p53 and AXIN2 genes (lane 4 of Figure 4b ). In ectopically expressed betaTrCP gene, the level of b-catenin protein was lower compared to the original H1299 cells (lane 7 of Figure 4b ). The results suggest that AXIN2 and betaTrCT augment the functional p53 downregulation of b-catenin expression.
Correlation of the expressions of AXIN2 proteins with prognosis in NSCLC patients
To define the prognostic effects of alteration of AXIN2, betaTrCP, b-catenin and p53 in lung cancer patients, survival curves of 110 patients were estimated using the Kaplan-Meier method. Interestingly, our results showed that loss of AXIN2 protein were associated with poor survival in unadjusted analysis (P ¼ 0.046, Figure 5a ) and in early stage NSCLC patients (P ¼ 0.016; Figure 5b ).
Discussion
In an effort to better understand the mechanism of alterations in AXIN2, betaTrCP and p53 status on nuclear b-catenin accumulation in NSCLC patients, we carried out a comprehensive molecular analysis of AXIN2, betaTrCP and p53 genes and examined their relationship with the prognostic data as well as b-catenin accumulation in 110 NSCLC patients. We found decreased AXIN2 (35%), decreased betaTrCP (18%) and p53 overexpression (62%) in NSCLC tumors examined. The b-catenin deregulation correlated significantly with the inactivation of AXIN2 and p53 accumulation, but not with the mutation of b-catenin. Furthermore, we demonstrated that AXIN2 and betaTrCP augment the reciprocal relationship between p53 and b-catenin expression in cell models. Our study is the first to identify the correlation of decreased mRNA/ protein expression with promoter hypermethylation and deacetylation of AXIN2 and betaTrCP genes and to show that their alterations are associated with an increase of b-catenin transactivation in NSCLC. We also observed that low expression of AXIN2 was significantly associated with poor survival. The data provide new evidence for a diverse mechanism leading to wild-type b-catenin nuclear accumulation in the NSCLC tumorigenesis, such as deregulation of AXIN2/betaTrCP destruction system and p53-mediated reduction for b-catenin accumulation.
The clinical data suggest that promoter hypermethylation is involved in the deregulation of the AXIN2 and betaTrCP genes (Figure 2) . We further confirmed in cell models that epigenetic silencing of AXIN2 and betaTrCP is relevant to hypermethylation and histone deacetylation (Figure 3) . This is the first study to show that promoter hypermethylation and deacetylation both contribute to decreased mRNA/protein expression of both AXIN2 and betaTrCP genes in lung cancer. Reactivation of AXIN2 and betaTrCP indeed reduced b-catenin transactivation as evident by low mRNA expression of several target genes of b-catenin. Our data provide new evidence for b-catenin accumulation through epigenetic inactivation of AXIN2/betaTrCPmediated stability control in lung cancer. However, mutations of AXIN2 and betaTrCP were implicated in colorectal and gastric carcinogenesis (Liu et al., 2000; Kim et al., 2007) . Therefore, detailed mutational analysis on AXIN2 and betaTrCP genes can provide a better understanding of lung tumorigenesis. (Levina et al., 2004) . Our study confirms that the effect of p53-mediated reduction in b-catenin level can also be exerted by The notion that destruction complex and p53 protein modulate the level of b-catenin was also supported by our clinical data. Significant correlation of p53 overexpression and low AXIN2 expression resulting in b-catenin accumulation was observed (Figure 1) . However, eight patients with positive expression of AXIN2 and betaTrCP without p53 overexpression showed b-catenin protein accumulation. It is possible that b-catenin accumulation could result from the loss of function in other genes such as Siah-1/SIP/Ebi complex in b-catenin degradation machinery (Liu et al., 2001 ). In addition, we observed that loss of AXIN2 protein expression was significantly associated with poor survival in early stage NSCLC patients, suggesting that AXIN2 could be a prognostic factor in lung cancer. Consistent with our results, another study pointed out that loss of AXIN2 in tumors can confer a survival disadvantage (Hughes and Brady, 2005) . Furthermore, forced expression of AXIN2 causes rapid cell death in colon cancer cell lines (Koinuma et al., 2006) . Identification of prognosis factors, especially in early stage cancer patients, is important for reducing cancer mortality because the individual at risk for tumor progression can be treated with adjuvant therapy and more frequent follow-up checks.
Our clinical and cell model findings offer a new mechanism, that is, high level of p53 could downregulate b-catenin expression, but this effect was attenuated by blocking the activities of AXIN2 and/or betaTrCP expression in NSCLC (Figure 4c ). Alterations in other components of Wnt/b-catenin signaling in lung cancer are under investigation to more clearly delineate the etiology of this disease in relation to Wnt/b-catenin signaling. Epigenetic control therapy may have potential as adjuvant treatment of lung cancer. The search for antagonists or agonists of the destruction complex of b-catenin might also lead to the discovery of compounds that have potential for lung cancer treatment.
Materials and methods
Sample preparation and clinical characterization of patients Non-small cell lung cancer patients were recruited at the Taipei Veterans General Hospital between 2002 and 2004 after obtaining appropriate institutional review board permission and informed consent from the patients. Table 1 includes the complete clinicopathologic data in this cohort of 110 NSCLC patients. The histology of the tumor types and their stages were determined according to the World Health Organization classification and the TNM system, respectively. Overall survival was calculated from the day of surgery to the date of death or the last follow-up. The mean follow-up period was 32.8 months (range: 2-61 months). For the LOH, methylation and mutation assay, genomic DNA from matched pairs of primary tumors and nearby normal lung tissues was prepared using proteinase K digestion and phenol-chloroform extraction. For the RNA expression assay, total RNA was prepared from tumors and normal lung tissues using Trizol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using SuperScript reverse transcriptase (Invitrogen) according to the manufacturer's instructions.
Immunohistochemical analysis
Paraffin blocks of tumors were cut into 5 mm slices and then processed using standard deparaffinization and rehydration techniques. Polyclonal antibodies for b-catenin (1:1500) (Transduction Laboratories, Lexington, KY, USA), APC (1:200) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), AXIN2 (1:500) (Santa Cruz Biotechnology), betaTrCP (1:800) (Santa Cruz Biotechnology) and p53 (1:200) (DAKO AB, Glostrup, Denmark) were used as primary antibodies to detect protein expression. If positive immunostaining was observed in the surrounding normal cells, the assessment of immunostaining was limited to the tumor cells. Staining was scored 3, 2, 1 or 0 if >70, 36-70, 5-35 or o5%, respectively, of tumor cell nuclei were positively stained for b-catenin and p53, and tumor cytoplasm was positively stained for APC, AXIN2 and betaTrCP. A score of 3 indicated b-catenin accumulation (Kase et al., 2000) and a score of 1 or 0 indicated the presence of little or no APC, AXIN2 and betaTrCP. In addition, p53 stains were graded as overexpressive when >25% tumor cells were positive (Wang et al., 2005) .
Mutation analysis of b-catenin
Exon 3 of b-catenin, a mutation hotspot region containing the GSK3 phosphorylation sites (Shigemitsu et al., 2001) , was amplified from genomic DNA for 35 cycles using the primers listed in Supplementary Table 1. Sequencing was performed in an ABI Prism 377 DNA Sequencer (PE Applied Biosystems, Foster City, CA, USA). The sequencings were verified in both forward and reverse directions.
Loss of heterozygosity analysis
Genomic DNA (20 ng) from normal lung cells or the tumor samples were used for each PCR analysis. The microsatellite Total number of samples is less than 110 because there was no complete clinicopathological registry in some cases.
The role of AXIN2, betaTrCP and p53 in Wnt/b-catenin pathway R-C Tseng et al markers located near the gene loci were D5S489 (APC), D5S492 (APC), D10S1239 (betaTrCP), D17S1882 (AXIN2) and D17S1825 (AXIN2). The primer sequences were obtained from Research Genetics (Huntsville, AL, USA). PCR products were mixed with fluorescent molecular weight markers for subsequent electrophoresis in a MegaBACE 1000 automatic sequencer (Amersham Pharmacia, Piscataway, NJ, USA). Allele sizes were determined using Genetic Profiler Analysis version 2.0 software. The allelic ratio was calculated as previously described (Tseng et al., 2005) .
Analysis of mRNA expression AXIN2, betaTrCP, c-myc and cyclin D1 mRNA expression were assayed in a multiplex RT-PCR analysis using the GAPDH gene as an internal control. Primers of AXIN2 and betaTrCP for the RT-PCR are listed in Supplementary Table 1 .
The primers for c-myc and cyclin D1 genes were as described by Koch et al. (2005) . Reactions were carried out in a volume of 25 ml with 1 ml of cDNA and 0.25 pmol of primers in a DNA Thermal Cycler. The relative levels of gene expression were studied by multiplex RT-PCR assay as previously described (Wang et al., 2005; Lee et al., 2007) .
Methylation-specific PCR (MSP) assay and bisulfite genomic sequencing The methylation status in the promoter region of the AXIN2 and betaTrCP genes was determined by chemical treatment with sodium bisulfite and subsequent MSP analysis. The primers for the bisulfite-converted sequence are listed in Supplementary Table 1 . Exactly 100 ng of bisulfite-modified DNA was amplified by PCR for 35 cycles. Positive control samples with unmethylated lymphocyte DNA and SssI methyltransferase-treated methylated DNA were also included for each set of PCR. The hypermethylation genes were defined as the amplification of more M products than U products from the tumor sample (Derks et al., 2004) . In addition, the PCR products of 10 tumor samples were purified using a QIAquick PCR purification kit (QIAGEN, Valencia, CA, USA) and then sequenced by forward and reverse primers in an ABI Prism 377 DNA Sequencer (PE Applied Biosystems).
5-aza-dC and SAHA treatment of lung cancer cells
The human lung cancer cell line CL1-5-F4 was kindly provided by Dr P-C Yang (Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan) (Chu et al., 1997) . The A549 cell was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were plated at 10 5 per 100-mm culture dish on the day before treatment. The cultures were treated for three doubling times with 2 mM 5-aza-dC and for 48 h with 5 mM SAHA. The cells were then harvested for an analysis of MSP, RT-PCR and Western blot assays.
Knockdown or ectopically expressed AXIN2, betaTrCP and p53 analysis we used pGIPZ lentiviral vetor (empty vector without a shRNAmir insert)-mediated shRNA-p53 (Open Biosystem, Drive Huntsville, Australia) technology to generate knocked down clones for p53 gene. To generate pCMV-SPORT6-AXIN2, the pCMV-SPORT6-betaTrCP expression plasmid, pCMV-SPORT6 plasmid and pCR4-AXIN2 plasmid were purchased from GENDISCOVERY (Open Biosystem). The pCR4-AXIN2 was partially digested with EcoRI and subcloned into EcoRI-digested pCMV-SPORT6 to generate pCMV-SPORT6-AXIN2. The A549 (with wild-type p53) and H1299 (with null p53, purchased from ATCC) cells (1 Â 10 5 ) were transiently transfected with 5 mg of shRNA and/or plasmid DNA using ExGen 500 transfection reagent (Fermentas, St Leon-Rot, Germany) as recommended by the manufacturer. Cells were harvested after 48 h and checked for specific silencing and ectopic expression of the target gene using Western blot assay.
Western blot analysis
The cells were lysed on ice using RIPA buffer (0.05 M Tris-HCl, pH 7.4, 0.15 M NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA, 0.5 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 5 mg/ml leupeptin and 10 mg/ml aprotinin). Lysates were centrifuged at 13 000 r.p.m. for 10 min at 4 1C; SDS gel loading buffer (60 mM Tris base, 2% SDS, 10% glycerol and 5% b-mercaptoethanol) was added and samples containing equal amounts of protein (50 mg) were separated on an 8% SDS-polyacrylamide gel electrophoresis and then electroblotted onto Immobilon-P membranes (Millipore Co., Bedford, MA, USA) in a transfer buffer. Immunoblotting was performed using antibodies against AXIN2 (1:200), betaTrCP (1:200), b-catenin (1:800) and p53 (1:500). b-actin (1:1000, Abcam Ltd., Cambridge, UK) was used as an internal control to confirm that equal amount of proteins were loaded.
Statistical analysis
Pearson's w 2 test was used to compare the frequency of b-catenin, AXIN2, and betaTrCP alterations in NSCLC patients with different clinical characteristics, including age, sex and smoking status, and various clinicopathological parameters, such as tumor type and tumor stage. For the staging of the primary tumor, patients in stages I and II were pooled into the early stage category and those with stages III and IV, into the late stage category. Type III censoring was performed on subjects who were still alive at the end of the study. Survival curves were calculated by univariate and multivariate analyses according to the Kaplan-Meier method, and comparison was performed by the log-rank test. Pp0.05 was considered to be statistically significant.
Abbreviations
NSCLC, non-small cell lung cancer; RT-PCR, reverse transcriptase-PCR; MSP, methylation-specific PCR; LOH, loss of heterozygosity; 5-aza-dC, 5-aza-2 0 -deoxycytidine; SAHA, suberoylanilide hydroxamic acid.
